Compare RMCF & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCF | BOLT |
|---|---|---|
| Founded | 1981 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0M | 7.7M |
| IPO Year | 2024 | 2021 |
| Metric | RMCF | BOLT |
|---|---|---|
| Price | $0.65 | $5.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 25.5K | ★ 698.9K |
| Earning Date | 10-19-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,432,352.00 | $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.66 | $5.61 |
| 52 Week High | $2.99 | $14.40 |
| Indicator | RMCF | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 27.72 | 35.41 |
| Support Level | N/A | N/A |
| Resistance Level | $1.19 | $8.72 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 0.08 | 7.96 |
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The company prepares numerous products, including caramel apples in the store. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, and Others. The company derives maximum revenue through manufacturing activities. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.